[Clinical and economic repercussions of changing the erythropoietin administration route].
Rodríguez
J R
JR
Ruiz
E
E
Vázquez
G
G
Ruiz Cicero
E
E
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D000075202:Contraindications; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D004921:Erythropoietin / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007501:Iron / Q000097:blood; D013030:Spain
D006454:Hemoglobins; D004921:Erythropoietin; D007501:Iron